Glucotrack Secures Key Patent for Implantable CGM Device

Glucotrack, Inc. (Nasdaq: GCTK) announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application that broadens the intellectual property protection for its implantable continuous blood glucose monitoring (CBGM) platform. This development brings the company closer to commercializing its device.

The Product

Glucotrack's CBGM is a fully implantable biosensor designed for continuous glucose monitoring in diabetic patients. The new patent adds to the company's IP portfolio, which already includes three CBGM patents issued in 2025.

Pricing and Availability

Glucotrack has not yet announced a specific launch date or pricing. However, securing the patent removes a key regulatory hurdle, paving the way for an FDA submission and eventual market entry.

Competition

The continuous glucose monitoring (CGM) market is currently dominated by major players like Dexcom and Abbott Laboratories. Glucotrack's device is differentiated by being fully implantable, potentially offering advantages in convenience and long-term accuracy.

Potential Impact on the Company

This milestone is a significant step toward commercializing the CBGM technology, potentially opening up a multi-billion dollar market for Glucotrack. However, the company still needs to complete clinical trials and obtain FDA approval before it can generate revenue.